Retatrutide 20mg
Triple GLP-1 / GIP / Glucagon receptor agonist
≥99.0%
Third-Party
COA
Also available in 10mg · 30mg · 40mg · 50mg — compare all sizes
Complete your research kit
Also searched as: Reta, R3ta, Reta peptide, LY3437943
Third-Party Tested
HPLC & mass spec verified purity
Batch Specific COA
Certificate with every batch
Discreet Packaging
Plain, unbranded, tamper-evident
Same-Day Dispatch
Before 2PM AEST, Australia-wide
Retatrutide 20mg is a research compound supplied for laboratory and scientific investigation into multi-receptor metabolic signalling. Retatrutide is a single peptide-based compound designed to interact experimentally with glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP) and glucagon receptors. This triple-receptor profile has made Retatrutide 20mg an area of interest in metabolic, endocrine and cellular signalling research. It is intended strictly for controlled research environments and is not supplied for human consumption or therapeutic use.
What Is Retatrutide 20mg?
Retatrutide is an investigational peptide that acts as a triple agonist at the GLP-1, GIP and glucagon receptor systems. These receptors are involved in overlapping but distinct metabolic pathways, including glucose regulation, energy balance, nutrient signalling and endocrine responses.
The 20mg format provides researchers with a defined nominal quantity for laboratory studies examining receptor activity and downstream signalling. Research involving Retatrutide commonly focuses on understanding how simultaneous activation of three metabolic receptor pathways may influence experimental models compared with single- or dual-receptor approaches.
Key Research Areas
Retatrutide 20mg has been investigated in relation to several areas of metabolic and endocrine research, including:
Research findings should be interpreted according to the experimental model used. Preclinical or early-stage findings should not be presented as established therapeutic outcomes.
Why Researchers Study Retatrutide 20mg
Retatrutide is scientifically interesting because it combines activity at three receptor systems within a single investigational molecule. GLP-1 and GIP receptors are associated with incretin-related signalling, while glucagon receptor activity contributes additional metabolic signalling pathways.
Studying these mechanisms together allows researchers to investigate receptor cross-talk, downstream signalling and broader metabolic responses under controlled conditions. The compound is therefore particularly relevant to research exploring multi-agonist peptide design and the biological consequences of activating several metabolic pathways simultaneously.
Key Research Areas at a Glance
Retatrutide 20mg in Australia
Researchers looking for Retatrutide 20mg Australia products should review the product specification, batch documentation, stock status and available analytical information before ordering. Availability, pricing and Australian domestic shipping conditions should be confirmed directly from the current product listing.
Retatrutide 20mg online listings intended for research should clearly distinguish laboratory supply from therapeutic or personal-use products.
Specifications
Certificate of Analysis
Quality, Purity and Batch Testing
Researchers should confirm the analytical specification for each Retatrutide 20mg batch before beginning laboratory work. Relevant documentation may include information on nominal vial quantity, analytical purity, identity testing and batch-specific Certificate of Analysis data where provided by the supplier.
Analytical purity should not be interpreted as evidence of clinical safety, therapeutic effectiveness or suitability for human use.
Storage & Handling
Storage and Laboratory Handling
Retatrutide 20mg should be handled according to the supplier’s verified batch documentation and the laboratory’s established peptide-handling procedures.
Storage temperature, reconstitution conditions, solvent selection and post-reconstitution stability should not be assumed without validated product documentation. Researchers should consult the applicable Certificate of Analysis, technical data sheet or laboratory protocol before use.
Reconstitution calculator: Retatrutide 20mg
Work out concentration and the volume to draw for each aliquot before you add diluent.
- Concentration
- –
- Volume per aliquot
- –
- On a 1 mL (U-100) syringe
- –
- Aliquots per vial
- –
A laboratory arithmetic aid only. Verify every calculation independently. Not dosing guidance; research use only.
Retatrutide 20mg: Frequently Asked Questions
It is an investigational triple-receptor agonist supplied in a nominal 20mg research format for laboratory investigation.
It is designed to activate GLP-1, GIP and glucagon receptors, allowing researchers to study combined metabolic signalling.
Because it targets three distinct receptor systems within one investigational peptide.
Research includes metabolic signalling, endocrine pathways, glucose regulation and receptor-interaction studies.
Researchers should refer to the current batch documentation for verified purity information.
CoA availability should be confirmed against the specific batch supplied.
Follow verified supplier documentation and approved laboratory handling protocols.
It may be sourced from Australian research-peptide suppliers where legally and commercially available. Confirm stock, price, documentation and shipping before ordering.
No. This product is supplied strictly for in-vitro laboratory research. It is not approved for human or veterinary use and must not be consumed or administered.
Orders placed before 2PM AEST on business days are dispatched the same day from Melbourne. Standard Post takes 3–7 business days and Express Post 1–3 business days, both tracked and discreet.
Purchase Other Quantities
Retatrutide is also available in other vial sizes. Compare the current formats below and jump straight to the quantity that fits your protocol.
Reviews
There are no reviews yet.